Chiasma, Inc. CHMA
Set alert
As of Apr 24, 3:47 PM ET
52-week range unavailable
- Open
- 4.08
- Prev close
- 3.76
- Mkt cap
- 237.81M
- Vol
- 8.20M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.76
- High
- 4.10
- Forward P/E
- -5.30
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2021
- 50-d avg
- 4.35
- 200-d avg
- 3.86
- 1y target
- 0.00
News
5 years ago proactiveinvestors.co.uk
Amryt Pharma completes Chiasma acquisition
Amryt Pharma PLC has completed its acquisition of US group Chiasma Inc with Raj Kannan and Roni Mamluk joining the board as non-executive directors. Joe Wiley, Amryt's chief executive, said: “This…
5 years ago prnewswire.com
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the Firm
NEW YORK , July 10, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: 1Life Healthcare, Inc. (NASDAQ: ONEM) concerning…
5 years ago benzinga.com
Chiasma Files Mycapssa European Application For Acromegaly
Chiasma Inc (NASDAQ: CHMA) submitted a marketing application to the European Medicines Agency seeking approval of Mycapssa (oral octreotide capsules) as maintenance therapy for adults with…
5 years ago globenewswire.com
Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency
Submission supported by previously announced data from Phase 3 MPOWERED™ study Submission supported by previously announced data from Phase 3 MPOWERED™ study
5 years ago benzinga.com
Chiasma's Mycapssa Associated With Positive Patient-Reported Outcomes In Acromegaly Patients
Chiasma Inc (NASDAQ: CHMA) has presented patient-reported outcomes (PROs) data from its MPOWERED Phase 3 trial of Mycapssa for acromegaly, a hormonal disorder in which the pituitary gland produces…
5 years ago globenewswire.com
Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly
--Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®-- --Data presented at AACE…
5 years ago globenewswire.com
Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences
-- New clinical data accepted for oral and e-Poster presentation at AACE -- -- e-ECE clinical data previously presented at Endocrine Society's 2021 annual meeting --
5 years ago prnewswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UFS, FOE, CHMA, ACST; Shareholders are Encouraged to Contact the Firm
NEW YORK, May 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Domtar Corporation (NYSE: UFS) concerning potential…
5 years ago zacks.com
Chiasma (CHMA) is Overbought: Is A Drop Coming?
Chiasma (CHMA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
5 years ago seekingalpha.com
Amryt Pharma plc (AMYT) Amryt Pharma Acquisition of Chiasma Inc. and Q1 2021 Earnings Conference (Transcript)
Amryt Pharma plc (AMYT) Amryt Pharma Acquisition of Chiasma Inc. and Q1 2021 Earnings Conference (Transcript)
5 years ago prnewswire.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chiasma, Inc. - CHMA
NEW YORK, May 7, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class…
5 years ago prnewswire.com
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Chiasma, Inc.
NEW YORK, May 5, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Chiasma, Inc. (NASDAQ: CHMA) and its board of directors concerning the proposed…
5 years ago benzinga.com
Why Chiasma's Stock Is Surging Today
Chiasma (NASDAQ:CHMA) shares are trading higher after Amryt announces that it has signed a definitive agreement to acquire Chiasma in an all-stock combination. Chiasma is currently up 39.78% to a…
5 years ago businesswire.com
Chiasma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Chiasma, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CHMA
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Chiasma, Inc. (NASDAQ: CHMA) to Amryt Pharma plc is fair to Chiasma shareholders.…
5 years ago pennystocks.com
Hot Penny Stocks to Buy? 3 to Watch on Cinco De Mayo
Penny stocks are making big waves on Cinco De Mayo; are these 3 worth watching? The post Hot Penny Stocks to Buy?
5 years ago pulse2.com
CHMA Stock: From $2.84 To $4.07 (43.31% Increase) Pre-Market Explanation
The stock price of Chiasma Inc (NASDAQ: CHMA) increased from $2.84 to $4.07 (up 43.31%) pre-market. This is why it happened.
5 years ago globenewswire.com
Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt
Announced agreement to merge with Amryt
5 years ago pulse2.com
CHMA Stock Price Increases Over 10% Pre-Market: Why It Happened
The stock price of Chiasma Inc (NASDAQ: CHMA) increased by over 10% pre-market. This is why it happened.
5 years ago globenewswire.com
Chiasma Presents Long-Term Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly at ENDO 2021
--93% of all patients who enrolled as a responder to MYCAPSSA ® maintained their biochemical response at the end of the 48-week open-label extension (OLE) period-- --Safety profile during the OLE was…
5 years ago globenewswire.com
Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021
--Data supports MYCAPSSA® as non-inferior to long-acting injectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly…
-
5 years ago benzinga.com
38 Stocks Moving in Tuesday's Pre-Market Session
Gainers INVO Bioscience, Inc. (NASDAQ: INVO) shares rose 108.4% to $6.48 in pre-market trading after the company announced an amendment under its exclusive U.S. commercialization agreement with…
-
5 years ago benzinga.com
Earnings Scheduled For March 4, 2021
Companies Reporting Before The Bell • Toro (NYSE:TTC) is expected to report quarterly earnings at $0.75 per share on revenue of $851.38 million.
-
5 years ago benzinga.com
Earnings Scheduled For November 5, 2020
Companies Reporting Before The Bell • Bluerock Residential Growth REIT, Inc. Class A Common Stock (AMEX:BRG) is expected to report quarterly loss at $0.64 per share on revenue of $52.59 million.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Thursday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Stocks That Hit 52-Week Lows On Friday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Thursday
-
8 years ago benzinga.com
Stocks Which Set New 52-Week High Friday, September 21
Stocks Which Set New 52-Week High Friday, September 21
-
8 years ago benzinga.com
38 Stocks Moving In Tuesday's Mid-Day Session
38 Stocks Moving In Tuesday's Mid-Day Session